Addressing COVID-19 vaccine hesitancy
This article seeks to summarize the currently available information to address the most common concerns regarding COVID-19 vaccination.
Older adults and COVID-19 vaccines
What do we know so far about older adults and COVID-19 vaccines? How long does the effect of the vaccine last and how successful have countries been in vaccinating older adults? WHO’s Dr Katherine O’Brien explains in Science in 5
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.
Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar
We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022.
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
Walk the talk on immunisation
With a wealth of experience, Professor of Epidemiology and former Minister of Health, ESWI Board Member Roman Prymula gives a personal testimony of the COVID-19 pandemic and the different perspectives of politics vs science when it comes to health policy.
Options for global and accessible vaccines – Rino Rappuoli
ESWI Summit 2022 – Stakeholder Debate
A mucosal perspective on pandemics
"Learn about the fascinating field of mucosal immunology, vaccine effectiveness, and the role of face-mask protection not from virus particles but “spiticles and snoticles”. Dr Peter Openshaw, ESWI Board Member and Professor of Experimental Medicine, ...
World Influenza Conference
September 17-18 2022, Shenzen China - Virtual
Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change
Organismal ageing is associated with many physiological changes, including differences in the immune system of most animals.